ArticleDisease models & mechanisms2021
High-dose vitamin B1 therapy prevents the development of experimental fatty liver driven by overnutrition.
Article in Disease models & mechanisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 34 citations in OpenAlex.
- Trial
- Lactobacillus protects against lead-induced hepatotoxicity by preserving the gut barrier and microbiota remodeling.BMC microbiology · 2026Article
- Sex-based multiomics analysis uncovers metabolic and molecular mediators linking MASH and atherosclerosis.JHEP reports : innovation in hepatology · 2026Article
- The Gut Commensal Butyricimonas Virosa Modulates Gut Microbiota-Dependent Thiamine Metabolism and Attenuates Mouse Steatotic Liver Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Precision nutrition for NAFLD: a mechanistic rationale for targeting the cytokine landscape.Frontiers in cell and developmental biology · 2026Review
- Thiamine Diphosphate Supplementation as a Heat-Stress Mitigation Strategy for Hair Male and Female Lambs in Feedlot: Physiological Responses, Growth Performance, and Carcass Traits.Animals : an open access journal from MDPI · 2025Article
- Exploring the role of gut microbiota in inflammatory bowel disease patients comorbid with non-alcoholic fatty liver disease.Gut pathogens · 2025Article
- Alcohol Consumption and Liver Metabolism in the Era of MASLD: Integrating Nutritional and Pathophysiological Insights.Nutrients · 2025Review
- Discovery of robust and highly specific microbiome signatures of non-alcoholic fatty liver disease.Microbiome · 2025Article
- Thiamine as a putative natural modulator of PPARγ: exploring a nutrient-based approach for type 2 diabetes.Frontiers in pharmacology · 2025Article
- Multi-omics analyses reveal altered gut microbial thiamine production in obesity.Frontiers in microbiology · 2025Article
- Review
- Ornithine aspartate effects on bacterial composition and metabolic pathways in a rat model of steatotic liver disease.World journal of hepatology · 2024Article
- Examining the Pathogenesis of MAFLD and the Medicinal Properties of Natural Products from a Metabolic Perspective.Metabolites · 2024Review
- The importance of thiamine (vitamin B1) in humans.Bioscience reports · 2023Article
- Alterations in nutrient digestion and utilization associated with different residual feed intake in Hu sheep.Animal nutrition (Zhongguo xu mu shou yi xue hui) · 2023Article
- Association between dietary intakes of B vitamins and nonalcoholic fatty liver disease in postmenopausal women: a cross-sectional study.Frontiers in nutrition · 2023Article
- MLGL-MP: a Multi-Label Graph Learning framework enhanced by pathway interdependence for Metabolic Pathway prediction.Bioinformatics (Oxford, England) · 2022Article
- The role of pancreas to improve hyperglycemia in STZ-induced diabetic rats by thiamine disulfide.Nutrition & diabetes · 2022Article
- Luteolin alleviates methionine-choline-deficient diet-induced non-alcoholic steatohepatitis by modulating host serum metabolome and gut microbiome.Frontiers in nutrition · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fatty liver is an abnormal metabolic condition of excess intrahepatic fat. This condition, referred to as hepatic steatosis, is tightly associated with chronic liver disease and systemic metabolic morbidity. The most prevalent form in humans, i.e. non-alcoholic fatty liver, generally develops due to overnutrition and sedentary lifestyle, and has as yet no approved drug therapy. Previously, we have developed a relevant large-animal model in which overnourished sheep raised on a high-calorie carbohydrate-rich diet develop hyperglycemia, hyperinsulinemia, insulin resistance, and hepatic steatosis. Here, we tested the hypothesis that treatment with thiamine (vitamin B1) can counter the development of hepatic steatosis driven by overnutrition. Remarkably, the thiamine-treated animals presented with completely normal levels of intrahepatic fat, despite consuming the same amount of liver-fattening diet. Thiamine treatment also decreased hyperglycemia and increased the glycogen content of the liver, but it did not improve insulin sensitivity, suggesting that steatosis can be addressed independently of targeting insulin resistance. Thiamine increased the catalytic capacity for hepatic oxidation of carbohydrates and fatty acids. However, at gene-expression levels, more-pronounced effects were observed on lipid-droplet formation and lipidation of very-low-density lipoprotein, suggesting that thiamine affects lipid metabolism not only through its known classic coenzyme roles. This discovery of the potent anti-steatotic effect of thiamine may prove clinically useful in managing fatty liver-related disorders.This article has an associated First Person interview with the joint first authors of the paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.